» Articles » PMID: 31266460

MAGENTA (Making Genetic Testing Accessible): a Prospective Randomized Controlled Trial Comparing Online Genetic Education and Telephone Genetic Counseling for Hereditary Cancer Genetic Testing

Abstract

Background: Studies have consistently indicated that the majority of individuals meeting the US Prevention Services Task Force guidelines for genetic testing have not had genetic counseling or testing. Despite increased availability and lower costs of multiplex cancer gene panels, there remains a gap in genetics services that has not been addressed by the current care delivery models. Lower cost of DNA sequencing with online patient-initiated ordering could increase test availability, but the ideal quantity and delivery method of patient education is not known. We hypothesized that online genetic education and testing with access to board certified genetic counselors could improve access to genetic testing while maintaining test quality and clinical utility. The MAGENTA (MAking GENetic Testing Accessible) trial is a nationwide randomized study designed to compare the effectiveness of online genetic education with pre- and post-test telephone genetic counseling to three potentially more accessible alternative approaches: online genetic education with optional telephone counseling, online genetic education with required pre-test telephone genetic counseling, and online genetic education with required post-test telephone genetic counseling.

Methods: 3000 women nationwide will undergo genetic testing for 19 hereditary cancer genes. This is a randomized four-arm non-inferiority study with equal randomization. The four study arms were selected to independently assess the delivery of genetic information both before and after genetic testing (pre-test and post-test) by either requiring telephone genetic counseling or providing only online education with optional telephone counseling. Patients have post-test telephone counseling when testing positive for a pathogenic inherited mutation in all four arms. Surveys measuring psychological, behavioral and cognitive state are completed online at baseline, 3 months, 12 months and 24 months post-results disclosure. The primary study outcome is cancer-risk distress at 3 months post-result disclosure.

Discussion: This trial will assess the use of a genetic service model using online access and electronic education, while evaluating the need for personal pre- and post-test genetic counseling. Data from this study may lead to increased options for delivery of genetic testing and possibly increase access to genetic testing. Identifying more individuals with inherited cancer susceptibility will allow targeted cancer prevention.

Trial Registration: Clinicaltrials.gov: NCT02993068 (registered December 14, 2016).

Citing Articles

Genetics Navigator: protocol for a mixed methods randomized controlled trial evaluating a digital platform to deliver genomic services in Canadian pediatric and adult populations.

DAmours G, Clausen M, Luca S, Reble E, Kodida R, Assamad D BMJ Open. 2024; 14(9):e090084.

PMID: 39231549 PMC: 11407190. DOI: 10.1136/bmjopen-2024-090084.


Genetic counselors' and community clinicians' implementation and perceived barriers to informed consent during pre-test counseling for hereditary cancer risk.

Capasso A, Nehoray B, Gorman N, Quinn E, Bucio D, Blazer K J Genet Couns. 2024; 34(1):e1887.

PMID: 38480478 PMC: 11393174. DOI: 10.1002/jgc4.1887.


Navigating the genetic landscape of breast cancer in South Africa amidst a developing healthcare system.

Oosthuizen J, van der Merwe N, Kotze M Front Genet. 2024; 14:1330946.

PMID: 38259622 PMC: 10800608. DOI: 10.3389/fgene.2023.1330946.


A novel system to provide information via online YouTube videos and an evaluation of current online information about hereditary breast cancer.

Iesato A, Fushimi A, Tahara R, Terada M, Iwase M, Kawamura C Breast Cancer. 2023; 31(1):63-74.

PMID: 37995024 PMC: 10764382. DOI: 10.1007/s12282-023-01512-y.


Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.

Rana H, Stopfer J, Weitz M, Kipnis L, Koeller D, Culver S JCO Oncol Pract. 2023; 19(11):1069-1079.

PMID: 37733980 PMC: 10667014. DOI: 10.1200/OP.23.00007.


References
1.
Schwartz M, Peshkin B, Hughes C, Main D, Isaacs C, Lerman C . Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol. 2002; 20(2):514-20. DOI: 10.1200/JCO.2002.20.2.514. View

2.
Cella D, Hughes C, Peterman A, Chang C, Peshkin B, Schwartz M . A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol. 2002; 21(6):564-72. View

3.
Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E . Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A. 2002; 116A(1):11-9. DOI: 10.1002/ajmg.a.10868. View

4.
Brehaut J, OConnor A, Wood T, Hack T, Siminoff L, Gordon E . Validation of a decision regret scale. Med Decis Making. 2003; 23(4):281-92. DOI: 10.1177/0272989X03256005. View

5.
Trepanier A, Ahrens M, McKinnon W, Peters J, Stopfer J, Grumet S . Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns. 2004; 13(2):83-114. DOI: 10.1023/B:JOGC.0000018821.48330.77. View